Retatrutide

Overview

Retatrutide is an investigational peptide that activates three hormone receptors involved in energy balance: GIP, GLP-1 and glucagon. Adding glucagon-receptor activity to the incretin pair is thought to increase energy expenditure on top of the appetite effects of GLP-1.

It is still in clinical development. A phase 2 obesity trial published in 2023 reported the largest average weight reduction seen with an incretin-based peptide at that time, and phase 3 trials are ongoing.

Research areas

• Body-weight regulation and energy expenditure
• Glycaemic control in type 2 diabetes models and trials
• Liver fat and metabolic dysfunction-associated steatotic liver disease
• Contribution of glucagon-receptor signalling to multi-agonist effects

Specifications

Category

Weight loss

Compound

Synthetic peptide, GIP / GLP-1 / glucagon receptor triple agonist

Structure

Single-chain peptide with a fatty acid side chain (development code LY3437943)

Form

Lyophilised (freeze-dried) powder in sealed vials

Available as

5mg (10 vials) · 10mg (10 vials) · 15mg (10 vials) · 20mg (10 vials) · 30mg (10 vials) · 40mg (10 vials) · 50mg (10 vials) · 60mg (10 vials) · single vial: 10mg, 20mg, 30mg

Quality

Third-party tested · certificate of analysis available

Storage and handling

Unopened vials: freezer (−20 °C) for long-term storage, or refrigerator (2–8 °C) for shorter periods. Keep away from light and moisture. After reconstitution, keep refrigerated.